<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>ChinaBio Partnering Forum</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>US capital crunch pushes China biotechs to roundabout financings</title>
      <description>
        <![CDATA[Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719777</guid>
      <pubDate>Tue, 29 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719777-us-capital-crunch-pushes-china-biotechs-to-roundabout-financings</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.webp?t=1651786531" type="image/png" medium="image" fileSize="321453">
        <media:title type="plain">China in red on globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinabio 2025: Europe-China pharma deals rise as US markets shut</title>
      <description>
        <![CDATA[Europe was a bigger counterpart to China in pharmaceutical dealmaking than the U.S. last year, speakers at Chinabio Partnering Forum said April 23, and the trend is likely to continue in 2025 with the shuttering of U.S. capital and volatility ailing global markets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719776</guid>
      <pubDate>Tue, 29 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719776-chinabio-2025-europe-china-pharma-deals-rise-as-us-markets-shut</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/deal-handshake2.webp?t=1588276885" type="image/png" medium="image" fileSize="341012">
        <media:title type="plain">Handshake with digital globe overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>US capital crunch pushes China biotechs to roundabout financings</title>
      <description>
        <![CDATA[Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719490</guid>
      <pubDate>Thu, 24 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719490-us-capital-crunch-pushes-china-biotechs-to-roundabout-financings</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.webp?t=1651786531" type="image/png" medium="image" fileSize="321453">
        <media:title type="plain">China in red on globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinabio 2025: Europe-China pharma deals rise as US markets shut</title>
      <description>
        <![CDATA[Europe was a bigger counterpart to China in pharmaceutical dealmaking than the U.S. last year, speakers at Chinabio Partnering Forum said April 23, and the trend is likely to continue in 2025 with the shuttering of U.S. capital and volatility ailing global markets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719591</guid>
      <pubDate>Wed, 23 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719591-chinabio-2025-europe-china-pharma-deals-rise-as-us-markets-shut</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/deal-handshake2.webp?t=1588276885" type="image/png" medium="image" fileSize="341012">
        <media:title type="plain">Handshake with digital globe overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Major 2024 licensing deals confirm Asia’s ascent from copier to innovator</title>
      <description>
        <![CDATA[From local drug discovery to global innovation, economic uncertainty is taking a toll on China’s innovative biotech system, forcing local companies to weather unpredictable storms, investors said during the Chinabio Partnering Forum in Shanghai in September.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715879</guid>
      <pubDate>Tue, 31 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715879-major-2024-licensing-deals-confirm-asias-ascent-from-copier-to-innovator</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/2024 year in review/Year-in-review-2024---Asia-deals-and-innovation.webp?t=1735587188" type="image/jpeg" medium="image" fileSize="163398">
        <media:title type="plain">Year in review 2024 - Asia deals and innovation</media:title>
      </media:content>
    </item>
    <item>
      <title>Major 2024 licensing deals confirm Asia’s ascent from copier to innovator</title>
      <description>
        <![CDATA[From local drug discovery to global innovation, economic uncertainty is taking a toll on China’s innovative biotech system, forcing local companies to weather unpredictable storms, investors said during the Chinabio Partnering Forum in Shanghai in September.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715776</guid>
      <pubDate>Mon, 30 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715776-major-2024-licensing-deals-confirm-asias-ascent-from-copier-to-innovator</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/2024 year in review/Year-in-review-2024---Asia-deals-and-innovation.webp?t=1735587188" type="image/jpeg" medium="image" fileSize="163398">
        <media:title type="plain">Year in review 2024 - Asia deals and innovation</media:title>
      </media:content>
    </item>
    <item>
      <title>Global economic uncertainty takes toll on China’s biotech ecosystem  </title>
      <description>
        <![CDATA[From local drug discovery to global innovation, economic uncertainty is taking a toll on China’s innovative biotech system, forcing local companies to weather unpredictable storms, investors said during the ChinaBio Partnering Forum in Shanghai Sept. 10-11.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712419</guid>
      <pubDate>Wed, 11 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712419-global-economic-uncertainty-takes-toll-on-chinas-biotech-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-structures-microscope.webp?t=1682529172" type="image/png" medium="image" fileSize="579163">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinese biotechs increasingly nimble in terms of deal structure </title>
      <description>
        <![CDATA[As geopolitical tensions rise between the U.S. and China, building cross-border relationships is more important than ever, said panelists during the Chinabio Partnering Forum in Shanghai Sept. 10.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712393</guid>
      <pubDate>Tue, 10 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712393-chinese-biotechs-increasingly-nimble-in-terms-of-deal-structure</link>
    </item>
    <item>
      <title>Chinabio 2023: Cansino, Gracell, Immuneonco’s C-suites offer IPO insights in China, US</title>
      <description>
        <![CDATA[Raising capital has always been a challenge for small to medium biotech firms worldwide, but the economic whiplash and the wider downturn across international markets post-pandemic have pushed Chinese biotechs to make-it-or-break-it scenarios for crossing the IPO threshold, speakers at the Chinabio Partnering Forum 2023 said in Shanghai.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701293</guid>
      <pubDate>Tue, 26 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701293-chinabio-2023-cansino-gracell-immuneoncos-c-suites-offer-ipo-insights-in-china-us</link>
    </item>
    <item>
      <title>Chinabio 2023: As tide turns to China, what will keep biotechs afloat in rocky capital, political seas?</title>
      <description>
        <![CDATA[“Why do the top 10 pharmaceutical companies remain in the top 10?” asked Li Chen, founder and CEO of Hua Medicine, to audience members at the Chinabio Partnering Forum in Shanghai on Sept. 20. “[It comes down to] their ability to innovate themselves, but also the capability to acquire technology from partnerships, [to] manufacture and sell in countries like the U.S."]]>
      </description>
      <guid>http://www.bioworld.com/articles/701292</guid>
      <pubDate>Tue, 26 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701292-chinabio-2023-as-tide-turns-to-china-what-will-keep-biotechs-afloat-in-rocky-capital-political-seas</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.webp?t=1651786531" type="image/png" medium="image" fileSize="321453">
        <media:title type="plain">China in red on globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinabio 2023: Big pharma scouts for innovation post-pandemic</title>
      <description>
        <![CDATA[Despite China’s near-frozen startup scene and increasingly cautious foreign investors following the COVID-19 pandemic, multinational pharmaceutical firms continued to scout for innovative up-and-coming Chinese biotechs in Shanghai at Chinabio Partnering Forum 2023 over its two-day run.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701291</guid>
      <pubDate>Tue, 26 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701291-chinabio-2023-big-pharma-scouts-for-innovation-post-pandemic</link>
    </item>
    <item>
      <title>Chinabio 2023: Big pharma scouts for innovation post-pandemic</title>
      <description>
        <![CDATA[Despite China’s near-frozen startup scene and increasingly cautious foreign investors following the COVID-19 pandemic, multinational pharmaceutical firms continued to scout for innovative up-and-coming Chinese biotechs in Shanghai at Chinabio Partnering Forum 2023 over its two-day run.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701252</guid>
      <pubDate>Mon, 25 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701252-chinabio-2023-big-pharma-scouts-for-innovation-post-pandemic</link>
    </item>
    <item>
      <title>Chinabio 2023: Cansino, Gracell, Immuneonco’s C-suites offer IPO insights in China, US</title>
      <description>
        <![CDATA[Raising capital has always been a challenge for small to medium biotech firms worldwide, but the economic whiplash and the wider downturn across international markets post-pandemic have pushed Chinese biotechs to make-it-or-break-it scenarios for crossing the IPO threshold, speakers at the Chinabio Partnering Forum 2023 said in Shanghai.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701145</guid>
      <pubDate>Thu, 21 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701145-chinabio-2023-cansino-gracell-immuneoncos-c-suites-offer-ipo-insights-in-china-us</link>
    </item>
    <item>
      <title>Chinabio 2023: As tide turns to China, what will keep biotechs afloat in rocky capital, political seas?</title>
      <description>
        <![CDATA[“Why do the top 10 pharmaceutical companies remain in the top 10?” asked Li Chen, founder and CEO of Hua Medicine, to audience members at the Chinabio Partnering Forum in Shanghai on Sept. 20. “[It comes down to] their ability to innovate themselves, but also the capability to acquire technology from partnerships, [to] manufacture and sell in countries like the U.S."]]>
      </description>
      <guid>http://www.bioworld.com/articles/701118</guid>
      <pubDate>Wed, 20 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701118-chinabio-2023-as-tide-turns-to-china-what-will-keep-biotechs-afloat-in-rocky-capital-political-seas</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.webp?t=1651786531" type="image/png" medium="image" fileSize="321453">
        <media:title type="plain">China in red on globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinabio Partnering Forum: Competition in dealmaking intensifies for Chinese biopharma</title>
      <description>
        <![CDATA[While partnering activities reached new highs in 2020, Chinese biopharma players found it more difficult to snatch good deals in a more competitive landscape. They now need to act faster and do more preparation work to seize partnering opportunities, panelists said at the Chinabio Partnering Forum.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507213</guid>
      <pubDate>Tue, 18 May 2021 13:02:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507213-chinabio-partnering-forum-competition-in-dealmaking-intensifies-for-chinese-biopharma</link>
    </item>
    <item>
      <title>Life sciences VC firms maturing in China with fast turnaround</title>
      <description>
        <![CDATA[Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507212</guid>
      <pubDate>Tue, 18 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507212-life-sciences-vc-firms-maturing-in-china-with-fast-turnaround</link>
    </item>
    <item>
      <title>Multinational corporations view China as source of innovation and accelerator of digital health</title>
      <description>
        <![CDATA[Multinational players are changing the way they look at China as a source for innovation as it accelerates efforts in areas such as digital health in pursuit of desire to make a global impact.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507211</guid>
      <pubDate>Tue, 18 May 2021 12:56:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507211-multinational-corporations-view-china-as-source-of-innovation-and-accelerator-of-digital-health</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Chinese-flag-and-microscopes.webp?t=1594666411" type="image/png" medium="image" fileSize="472941">
        <media:title type="plain">Chinese flag and microscopes</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinabio Partnering Forum: Competition in dealmaking intensifies for Chinese biopharma</title>
      <description>
        <![CDATA[While partnering activities reached new highs in 2020, Chinese biopharma players found it more difficult to snatch good deals in a more competitive landscape. They now need to act faster and do more preparation work to seize partnering opportunities, panelists said at the Chinabio Partnering Forum.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507099</guid>
      <pubDate>Fri, 14 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507099-chinabio-partnering-forum-competition-in-dealmaking-intensifies-for-chinese-biopharma</link>
    </item>
    <item>
      <title>Life sciences VC firms maturing in China with fast turnaround</title>
      <description>
        <![CDATA[Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/507075</guid>
      <pubDate>Thu, 13 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507075-life-sciences-vc-firms-maturing-in-china-with-fast-turnaround</link>
    </item>
    <item>
      <title>Multinational corporations view China as source of innovation and accelerator of digital health</title>
      <description>
        <![CDATA[Multinational players are changing the way they look at China as a source for innovation as it accelerates efforts in areas such as digital health in pursuit of desire to make a global impact. At the Chinabio Partnering Forum, panelists representing Pfizer Inc., Merck & Co. Inc., Sanofi SA and Johnson & Johnson all shared what they have witnessed there and how they’re already tapping China-sourced innovations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507030</guid>
      <pubDate>Wed, 12 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507030-multinational-corporations-view-china-as-source-of-innovation-and-accelerator-of-digital-health</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Chinese-flag-and-microscopes.webp?t=1594666411" type="image/png" medium="image" fileSize="472941">
        <media:title type="plain">Chinese flag and microscopes</media:title>
      </media:content>
    </item>
    <item>
      <title>China sees five-year highs in life sciences investments and partnering</title>
      <description>
        <![CDATA[China saw $28.5 billion invested in its life sciences sector in 2020, which was double the previous year’s amount and sets a five-year high. Partnering activities and IPOs also grew exponentially over the last five years to set records.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506978</guid>
      <pubDate>Tue, 11 May 2021 16:32:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506978-china-sees-five-year-highs-in-life-sciences-investments-and-partnering</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-opportunity-.webp?t=1588615041" type="image/png" medium="image" fileSize="139011">
        <media:title type="plain">Opportunity compass with Chinese flag</media:title>
      </media:content>
    </item>
    <item>
      <title>China sees five-year highs in life sciences investments and partnering</title>
      <description>
        <![CDATA[China saw $28.5 billion invested in its life sciences sector in 2020, which was double the previous year’s amount and sets a five-year high. Partnering activities and IPOs also grew exponentially over the last five years to set records.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506908</guid>
      <pubDate>Mon, 10 May 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506908-china-sees-five-year-highs-in-life-sciences-investments-and-partnering</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-opportunity-.webp?t=1588615041" type="image/png" medium="image" fileSize="139011">
        <media:title type="plain">Opportunity compass with Chinese flag</media:title>
      </media:content>
    </item>
    <item>
      <title>Despite COVID-19, China sees rebound in VC, IPOs and partnering in first six months</title>
      <description>
        <![CDATA[While the COVID-19 pandemic has brought disruptions to R&D, market activities in the biopharmaceutical sector have remained active during the first half of this year in China. Venture capital investments, IPOs and partnering activity showed upward trends, except for M&A activity, which has declined for two years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497256</guid>
      <pubDate>Tue, 01 Sep 2020 16:01:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497256-despite-covid-19-china-sees-rebound-in-vc-ipos-and-partnering-in-first-six-months</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-economy-trade.webp?t=1588614905" type="image/png" medium="image" fileSize="470040">
        <media:title type="plain">Chinese flag, charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Despite COVID-19, China sees rebound in VC, IPOs and partnering in first six months</title>
      <description>
        <![CDATA[While the COVID-19 pandemic has brought disruptions to R&D, market activities in the biopharmaceutical sector have remained active during the first half of this year in China. Venture capital investments, IPOs and partnering activity showed upward trends, except for M&A activity, which has declined for two years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497055</guid>
      <pubDate>Wed, 26 Aug 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497055-despite-covid-19-china-sees-rebound-in-vc-ipos-and-partnering-in-first-six-months</link>
    </item>
  </channel>
</rss>
